CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 285 enrolled
Drug / intervention
VVZ-149 Injections +1 moredrug
Likely dose
VVZ-149 Injections 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05764525
NCT05764525Phase 3Completed

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Postoperative Pain Following Laparoscopic Colectomy

Vivozon Pharmaceutical Inc.·interventional·Posted Mar 10, 2023·Updated Feb 20, 2025

In Brief

A Phase 3 clinical trial evaluating VVZ-149 Injections and Placebo for Pain, Postoperative and Acute Pain. Completed, enrolled 285 participants across 5 sites.

Detailed Summary

The purpose of this phase 3 study is to evaluate the efficacy and safety of VVZ-149 Injections for the treatment of postoperative pain following laparoscopic colectomy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedMar 10, 2023
Enrollment StartJul 19, 2021
Primary CompletionNov 3, 2022
Study CompletionNov 22, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 3.3 years ago

Interventions

VVZ-149 Injectionsdrug

IV infusion of 1000 mg of VVZ-149

Placebodrug

IV infusion of 0 mg of VVZ-149